- Home
- VGI vs JSPR Comparison
VGI vs JSPR Comparison
Compare VGI & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VGI | JSPR |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.0M | 26.3M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | VGI | JSPR |
|---|---|---|
| Price | $7.29 | $0.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 36.3K | ★ 672.8K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 12.66% | N/A |
| EPS Growth | N/A | ★ 19.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.18 | $0.32 |
| 52 Week High | $8.09 | $2.69 |
Technical Indicators
Market Signals| Indicator | VGI | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 48.45 |
| Support Level | $7.26 | $0.64 |
| Resistance Level | $7.54 | $1.01 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 36.62 | 51.20 |
Price Performance
Historical ComparisonAbout VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.